Compared with patients with baseline mucin-1 < 2.5 ng/mL, those with mucin-1 ≥ 2.5 ng/mL had higher risks of on-treatment AE-IPF and SAO (either early or anytime during the follow-up). Here, MUC1 is linked to southeast Asian ovalocytosis.